Jeri Kim,Associate Professor of The University of Texas MD Anderson Cancer Center, USA. Fundamental to her research is a clinical framework for studying low-volume prostate cancer to delineate underlying molecular mechanisms involved in prostate carcinogenesis and disease progression. She have been a Principal Investigator (PI) or Co-investigator for studies funded by the NCI, grants from private nonprofit groups, and internal grants—and perspective that best comes from experience: “dual citizenship” in clinical medicine and basic science. She have expanded my technical expertise in laser capture microdissection, oligonucleotide microarrays, and immunohistochemical studies (NCI-funded [R21 and R03] studies of prostate cancer multifocality); managed both clinical and tissue studies in an examination of the Prostate Cancer Prevention Trial finding of higher grade cancers in men taking finasteride (as PI of an N01 trial); and led tissue and clinical studies in a longitudinal study of early-stage prostate cancer in one of the largest active surveillance cohorts in the world (as PI). Building a multidisciplinary team of collaborators—pathologists, surgeons, biostatisticians, and oncologists—over time has streamlined operations, benefiting team members, the students who engage in the work, and the translations to improve clinical practice that we are attempting.